filgotinib

March 14, 2017

New Phase 2 Trials to Evaluate Filgotinib in Two Types of Crohn’s Disease

News

Galapagos NV, collaborating with Gilead Sciences, will soon begin recruiting for announced two new Phase 2 clinical trials to evaluate filgotinib in patients with small bowel Crohn’s disease, as well ... Read more

December 13, 2016

Galapagos Begins Phase 2b/3 Clinical Trial of Filgotinib in Ulcerative Colitis Patients

News

Galapagos NV recently announced that it has dosed the first patient with ulcerative colitis (UC) in its SELECTION Phase 2b/3 clinical trial, investigating the efficacy and safety of two doses ... Read more

December 1, 2016

Galapagos Starts Phase 3 Trial of Filgotinib for Crohn’s Disease

News

Galapagos, a clinical-stage biotech specializing in small molecule medicines, has dosed its first patient in its DIVERSITY (NCT02914561) Phase 3 clinical trial of filgotinib in Crohn’s disease. The trial is ... Read more

October 4, 2016

Galapagos Readies Two Clinical Trials To Advance Filgotinib as IBD Treatment

News

Galapagos has completed discussions with U.S. and European regulatory authorities to begin the DIVERSITY Phase 3 clinical trial (NCT02914561) in patients with Crohn’s disease and the SELECTION Phase 2b/3 study (NCT02914522) in ... Read more

October 3, 2016

Key Findings on Filgotinib Trial for Crohn’s to be Presented at UEG Week

News

Galapagos will present endoscopic improvements and other key findings from the FITZROY Phase 2 clinical trial of filgotinib in Crohn’s disease, during United European Gastroenterology Week (UEG Week), Oct. 15-19, in Vienna. ... Read more

April 28, 2016April 28, 2016

New Clinical Trial Data on Crohn’s Disease Treatment Filgotinib Reported by Galapagos

News

Beglium-based Galapagos NV recently reported additional data from its Phase 2 FITZROY clinical trial assessing filgotinib, a selective JAK1 inhibitor being investigated for the treatment of Crohn’s disease. The FITZROY trial assessed the efficacy and ... Read more

March 18, 2016March 18, 2016

Galapagos Reports Positive Phase 2 Trial Data of Crohn’s Disease Drug Filgotinib at ECCO Congress

Crohn's Disease, News

Galapagos recently presented data from the FITZROY Phase 2 clinical trial of filgotinib for Crohn’s disease at the 11th ECCO Congress in Amsterdam. Prof. Séverine Vermeire, lead investigator of the trial, presented ... Read more

August 7, 2015August 7, 2015

Galapagos Announces Last Patient Has Been Randomized in Crohn’s Disease Study With Filgotinib

Crohn's Disease, News

Galapagos NV a clinical-stage biotechnology company specializing in the discovery and development of small molecule medicines with novel modes of action, recently announced the last patient randomisation in their Phase ... Read more